India, Feb. 1 -- A research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel live-attenuated vaccine candidate,cb1, capable of generating broad immunity against a wide range of beta-coronaviruses with a single intranasal dose. The vaccine not only prevents severe disease, but also effectively blocks viral transmission in animal models, offering a promising strategy for pandemic preparedness against future coronavirus threats. The groundbreaking study was published in the journalProceedings of the National Academy of Sciences (PNAS) [link to the publication].
The new vaccine is based on arational attenuation strategy that alters the codon usage biasof the SARS-CoV-2 genome. This differs from t...